[CAS NO. 96829-58-2] Orlistat
PRODUCTS SPECIFICATIONS [96829-58-2]
DESCRIPTION [96829-58-2]
Overview
| MDL | MFCD05662360 |
|---|---|
| Molecular Weight | 495.73 |
| Molecular Formula | C29H53NO5 |
| SMILES | O=C1[C@@H](CCCCCC)[C@H](C[C@@H](OC([C@@H](N([H])C([H])=O)CC(C)C)=O)CCCCCCCCCCC)O1 |
6 Publications Citing Use of MCE
Summary
Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases . Orlistat is also an inhibitor of fatty acid synthase ( FASN ), is used orally for long-term research of obesity [1] . Anti-atherosclerotic effect [2] .
In Vitro
Orlistat (40 μM; 2 days) does not affect MGMT levels in a human melanoma cell line, but downregulates the repair protein by 30-70% in human peripheral blood mononuclear cells, in two leukemia and two colon cancer cell lines. Orlistat does not alter noticeably MGMT mRNA expression [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | The human melanoma cell line M10, Peripheral blood mononuclear cells , The human Jurkat CD4 + T cell leukemia cell line, the human promyelocytic leukemia cell line HL-60, the epithelial colon cancer HCT116 cells,non adherent mononuclear cells (NAMNC) [1] |
| Concentration: | 2.5, 5, 10, 20, 40 μM for Jurkat cells; 20 and 40 μM for HCT116 cells; 40 μM for normal NAMNC, M10 melanoma, HL-60 promyelocytic leukemia, and HT-29 colon cancer cells |
| Incubation Time: | 2 days for Jurkat cells; 2 or 4 days for HCT116 cells; 2 days for NAMNC, M10 melanoma, HL-60 promyelocytic leukemia, HT-29 colon cancer |
| Result: |
Reduced by >50% the MGMT level at the concentration of 40 μM for Jurkat cells, whereas little or no effect was found when lower concentrations were used.
Downregulation of MGMT expression is produced at 40 μM for HCT116 cells.
Provoked an ~50% reduction of MGMT level at 40 μM in normal NAMNC, and HL-60 promyelocytic leukemia, HT-29 colon cancer cells except for melanoma M10 cells that showed no downregulation of the protein. |
In Vivo
Orlistat (10 mg/kg/day) significantly improves lipid profile, increases antioxidant enzymes and expression of anti-inflammatory markers, and decreases the expression of the pro-inflammatory marker compared to the obese (OB) group [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Eighteen male rats of Sprague–Dawley strain aged between 8–10 weeks weighing 200-250 g [2] |
| Dosage: | 10 mg/kg/day |
| Administration: | Orally; six weeks |
| Result: | Treatment persistently restored the increased body weight, which was significantly observed at the ninth week until the end of the experimental period. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01003483 | Yazd Research & Clinical Center for Infertility|Yazd Medical University |
Obesity
|
December 1, 2008 | Phase 2 |
| NCT01184560 | Gachon University Gil Medical Center |
Obesity
|
February 2010 | Not Applicable |
| NCT00156897 | Alizyme |
Non-Insulin-Dependent Diabetes Mellitus|Obesity
|
December 2004 | Phase 2 |
| NCT03383068 | RenJi Hospital |
PCOS|Impaired Glucose Tolerance
|
January 1, 2018 | Phase 4 |
| NCT00461799 | University Medical Center Groningen|Erasmus Medical Center|De Najjar Stichting |
Crigler-Najjar Syndrome
|
September 2003 | Not Applicable |
| NCT02432209 | Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Penn State University|Augusta University|University of California, San Francisco|University of North Carolina|University of Oklahoma|University of Pennsylvania |
Infertility, Female
|
August 2015 | Phase 3 |
| NCT01351753 | University of Iowa |
Obesity|Metabolic Syndrome X
|
March 2011 | Phase 2 |
| NCT01755676 | EMS |
Obesity
|
September 2016 | Phase 3 |
| NCT01597531 | East Carolina University |
Type 2 Diabetes|Gastric Banding
|
June 2012 | Phase 4 |
| NCT02069197 | Mid-Atlantic Epilepsy and Sleep Center, LLC |
Obesity|Diabetes|Obstructive Sleep Apnea
|
January 2014 | Phase 2 |
| NCT05579249 | Novo Nordisk A+S |
Obesity
|
January 20, 2023 | Phase 4 |
| NCT01035333 | Albany College of Pharmacy and Health Sciences|Albany Medical College |
Obesity
|
November 2009 | Phase 4 |
| NCT00752726 | GlaxoSmithKline |
Obesity|Overweight
|
September 2008 | Phase 4 |
| NCT01675154 | University of Texas Southwestern Medical Center |
Type 1 Hyperlipoproteinemia
|
November 2015 | Phase 2 |
| NCT00212199 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Hoffmann-La Roche |
1. Obesity
|
January 2002 | Phase 4 |
| NCT00152360 | University of British Columbia |
Obesity|Heart Diseases
|
June 2005 | Phase 4 |
| NCT00991926 | Federico II University |
Obesity
|
December 2006 | |
| NCT00001723 | Jack Yanovski|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Roche Pharma AG|National Institutes of Health Clinical Center (CC) |
Diabetes Mellitus|Hypertension|Metabolic Disease|Obesity|Sleep Apnea Syndrome
|
May 1998 | Phase 2 |
| NCT01550926 | GlaxoSmithKline |
Overweight
|
February 2009 | Phase 1 |
| NCT01475019 | Aristotle University Of Thessaloniki |
Obesity|Polycystic Ovaries Syndrome
|
January 2004 | Phase 4 |
| NCT01387243 | GlaxoSmithKline |
Overweight
|
January 2010 | |
| NCT01797757 | Nestlé |
Obesity
|
January 2012 | Not Applicable |
| NCT05076474 | Shandong New Time Pharmaceutical Co., LTD |
Bioequivalence
|
October 1, 2020 | Not Applicable |
| NCT02706067 | Hoffmann-La Roche |
Obesity
|
July 2002 | Phase 4 |
| NCT03675191 | Gangnam Severance Hospital |
Obesity|Overweight
|
October 16, 2018 | Not Applicable |
| NCT05496075 | Shanghai 10th People´s Hospital |
Uric Acid
|
August 26, 2022 | Phase 3 |
| NCT01719419 | Pennington Biomedical Research Center |
Overweight
|
March 2012 | Not Applicable |
| NCT03582722 | Emory University|Healthway Compounding Pharmacy in central Michigan|Michigan Public Health Departments|National Institute of Environmental Health Sciences (NIEHS) |
Polybrominated Biphenyl Poisoning
|
September 14, 2018 | Phase 4 |
| NCT00292799 | Sheffield Teaching Hospitals NHS Foundation Trust|Hoffmann-La Roche |
Anovulation|Obesity
|
February 2006 | Not Applicable |
| NCT01170806 | University of Campinas, Brazil|Germed Pharma |
Obesity
|
October 2009 | Not Applicable |
| NCT03884127 | Fifth Affiliated Hospital of Xinjiang Medical University|West China Hospital |
Hyperlipidemia
|
April 1, 2019 | |
| NCT04531176 | The Cleveland Clinic |
Type 2 Diabetes|Obesity
|
September 1, 2020 | Phase 4 |
| NCT00160407 | St. Louis University|Hoffmann-La Roche |
Fatty Liver|Hepatitis
|
October 2003 | Phase 4 |
| NCT00422058 | Novo Nordisk A+S |
Metabolism and Nutrition Disorder|Obesity
|
January 10, 2007 | Phase 2 |
| NCT02767531 | University of Texas Southwestern Medical Center |
Hyperlipoproteinemia Type I|Hypertriglyceridemia
|
December 2015 | Phase 2 |
| NCT01047657 | University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo |
Asthma|Obesity|Weight Loss
|
November 2009 | Phase 3 |
| NCT00108524 | US Department of Veterans Affairs|VA Office of Research and Development |
Diabetes Mellitus|Obesity
|
July 2004 | Not Applicable |
| NCT01414465 | University of Campinas, Brazil|Germed Pharma |
Overweight
|
October 2009 | Not Applicable |
| NCT00940628 | Hoffmann-La Roche |
Obesity
|
April 2008 | Phase 3 |
| NCT01332448 | GlaxoSmithKline |
Obesity
|
February 2010 | |
| NCT02529631 | Certmedica International GmbH |
Overweight|Obesity
|
November 2009 | Not Applicable |
| NCT01126970 | Shionogi|Shionogi Inc. |
Obesity
|
April 2010 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 201.72 mM ; Need ultrasonic)
H 2 O : < 0.1 mg/mL (insoluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.0172 mL | 10.0861 mL | 20.1723 mL |
| 5 mM | 0.4034 mL | 2.0172 mL | 4.0345 mL |
| 10 mM | 0.2017 mL | 1.0086 mL | 2.0172 mL |
References
- [1] Giorgia Cioccoloni, et al. Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro. Int J Oncol. 2015 Aug;47(2):764-72.
- [2] Zaidatul Akmal Othman, et al. Anti-Atherogenic Effects of Orlistat on Obesity-Induced Vascular Oxidative Stress Rat Model. Antioxidants (Basel). 2021 Feb 6;10(2):251.
Synonyms